All In Biotech

Drug Trial Radar · NCT01323335

The Relationship Between Uric Acid and Inflammatory Markers

Last checked: Nov 20, 2026Latest source record: Jul 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

97

Actual

Start

Mar 31, 2009

Primary completion

Jan 31, 2014

Study completion Jan 31, 2014

Sponsor

Sponsor type
NIH
First posted
Mar 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Background: \- Uric acid is a substance found in the blood that may contribute to certain chronic medical conditions and disorders, such as diabetes, insulin resistance, and high blood pressure. High uric acid concentrations have been associated with stroke and heart disease, as well as chronic heart failure. In particular, researchers are interested in determining the relationship between uric acid and inflammatory markers, or chemicals in the blood that can indicate inflammation and other problems with the body. Objectives: * To study the specific effects of changes in uric acid in the body. * To determine whether uric acid contributes to inflammation in the body. Eligibility: \- Healthy individuals between 50 and 75 years of age. Design: * This study will involve four visits: a screening visit, two study visits, and a followup visit. * At the screening visit, participants will have a physical examination, blood and urine tests, and an electrocardiogram. Participants will be divided into two groups based on the existing amount of uric acid in their blood. * Within 7 days of the screening visit, participants will have a full-day study visit with a magnetic resonance imaging scan, followed by a high-fat meal and further blood samples collected over the following 8 hours. * At least 2 days after the first study visit, participants will have the second study visit, which will require a 2-night stay at the National Institutes of Health. Participants will have a metabolism test, and will receive the following infusions based on the groups they were assigned to at the screening visit. * Group A (low uric acid) will receive either uric acid or a placebo. * Group B (moderate to high uric acid) will receive either Rasburicase (a drug that reduces the amount of uric acid in the blood) or a placebo. * After the infusions and related blood tests, participants will have a high-fat meal with further blood and urine samples. * Approximately 2 weeks after the second study visit, participants will have a final followup visit with additional blood and urine tests to determine whether the levels of uric acid in the blood have returned to normal.

Conditions

  • Healthy Volunteers

Interventions

  • IV Uric AcidDrug

  • IV RasburicaseDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effects of uric acid on inflammatory markers

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute of Aging, Clinical Research Unit

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.